Methods of optimizing nucleotide sequences encoding engineered influenza proteins

Patent metadata

Field	Value
Publication number	US-2018162914-A1
Application number	US-201615580192-A
Country	US
Kind code	A1
Filing date	Jun 9, 2016
Priority date	Jun 9, 2015
Publication date	Jun 14, 2018
Grant date	—

Abstract

The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.

First claim

1 . A method of generating an optimized nucleotide sequence encoding an engineered influenza structural protein, the method comprising:
a) providing an amino acid sequence of the engineered influenza structural protein; b) reverse-translating the amino acid sequence to generate a first nucleotide sequence; c) identifying a second nucleotide sequence that encodes an influenza structural protein that shares a high degree of sequence identity with the engineered influenza structural protein; d) at every position where the codons in the first and second nucleotide sequences code for the same amino acid, changing codons in the first nucleotide sequence to match codons from the second nucleotide sequence; and e) at every position where the codons in the first and second nucleotide sequences code for a different amino acid, changing codons in the first nucleotide sequence to match codons that are based on structural protein-specific influenza codon usage preferences, thereby generating the optimized nucleotide sequence.

2 . The method of claim 1 , wherein the influenza structural protein that shares a high degree of sequence identity with the engineered influenza structural protein is a wild-type influenza structural protein.

3 . The method of claim 1 , further comprising adding the 5′ and 3′ non-coding sequences from a high titer rescued strain to the optimized nucleotide sequence.

4 . The method of claim 3 , wherein in the high titer rescued strain is A/PuertoRico/8/34 (PR8).

5 . The method of claim 1 , wherein the amino acid sequence of the engineered influenza structural protein encoded by the optimized nucleotide sequence is the same as the amino acid sequence encoded by the first nucleotide sequence.

6 . The method of claim 1 , wherein the optimized nucleotide sequence further comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence coding for a transmembrane domain, and/or a nucleotide sequence coding for a cytoplasmic domain.

7 . The method of claim 6 , further comprising exchanging the nucleotide sequence encoding the signal peptide in the optimized nucleotide sequence with a nucleotide sequence encoding the signal peptide from a high titer rescued strain.

8 . The method of claim 6 , further comprising exchanging the nucleotide sequence encoding the transmembrane domain with a nucleotide sequence encoding the transmembrane domain from a high titer rescued strain.

9 . The method of claim 6 , further comprising exchanging the nucleotide sequence encoding the cytoplasmic domain with a nucleotide sequence encoding the cytoplasmic domain from a high titer rescued strain.

10 . The method of claim 7 , wherein the high titer rescued strain is A/PuertoRico/8/34 (PR8).

11 . The method of claim 1 , wherein the engineered influenza structural protein is an influenza type A hemagglutinin protein.

12 . The method of claim 11 , wherein the hemagglutinin protein is a subtype selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and H17.

13 . The method of claim 1 , wherein the structural protein-specific influenza codon usage preferences are set forth in Tables 1-10.

14 . The method of claim 1 , wherein reverse translating the amino acid sequence to generate a first nucleotide sequence comprises use of a codon usage table specific for influenza viruses.

15 . The method of claim 1 , wherein the second nucleotide sequence encodes a wild type version of the influenza structural protein and is identified from a publicly available database comprising influenza nucleotide sequences.

16 . The method of claim 3 , wherein the 5′ non-coding sequence comprises the nucleotide sequence of SEQ ID NO: 23 and/or the 3′ non-coding sequence comprises the nucleotide sequence of SEQ ID NO: 24 or wherein the 5′ non-coding sequence comprises the nucleotide sequence of SEQ ID NO: 103 and/or the 3′ non-coding sequence comprises the nucleotide sequence of SEQ ID NO: 104.

17 . The method of claim 1 , wherein the engineered influenza structural protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, and SEQ ID NO: 102.

18 . A method of expressing the optimized nucleotide sequence generated by the method of claim 1 , the method comprising:
inserting the optimized nucleotide sequence into an expression plasmid; and expressing the optimized nucleotide sequence to generate the engineered influenza structural protein.

19 . A reverse genetics method for producing an infectious influenza virus, the method comprising:
transfecting mammalian cells with one or more expression vectors, wherein the one or more expression vectors comprise an optimized nucleotide sequence encoding an engineered influenza structural protein generated by the method of claim 1 and b) nucleotide sequences coding for influenza proteins from one or more donor viruses; producing the infectious influenza virus.

20 . The method of claim 19 , wherein the one or more donor viruses are selected from the group consisting of A/Puerto Rico/8/34 (H1N1) (PR8), B/Lee/40, and B/Panama/45/90.

21 . The method of claim 19 , wherein the infectious influenza virus is an infectious reassortant influenza virus comprising the genetic material of one or more donor viruses.

22 . (canceled)

23 . (canceled)

24 . A method of preparing an influenza vaccine composition, the method comprising:
generating a seed virus by transfecting mammalian cells with a set of expression vectors, one or more of which comprises an optimized nucleotide sequence encoding an engineered influenza structural protein generated by the method of claim 1 ; harvesting the seed virus; and producing infectious influenza virus by infecting eggs or mammalian cells with the seed virus; harvesting the infectious influenza virus after multiplication in the eggs or mammalian cells; purifying the harvested infectious influenza virus; optionally inactivating the purified virus; and mixing the purified virus with a pharmaceutically acceptable carrier.

25 . (canceled)

26 . (canceled)

Assignees

• Sanofi Pasteur Inc

Inventors

• Strugnell Tod Dwayne
• Cortes-Garcia Guadalupe
• Alefantis Tim

Classifications

• C12N2760/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2760/16222

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2800/22

  Vectors comprising a coding region that has been codon optimised for expression in a respective host · CPC title

• C12N2760/16234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title